Citron Research: Not Dialing Back Warning on Valeant Pharma (VRX), Dialing Back on Citron Focus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/25/2026

1. MU
2. QCOM
3. CBRS
4. HTZ
5. FDX
6. USO
7. SPY
8. KBH
9. LAES
10. GPUS

Go back to Citron Research: Not Dialing Back Warning on Valeant Pharma (VRX), Dialing Back on Citron Focus

Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI

November 2, 2015 9:04 PM EST

Evercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.

Raffat highlighted the following from the letter:

For... More

Dead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?

November 2, 2015 3:17 PM EST

Citron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More

Valeant Pharma (VRX) on Watch Ahead of Citron Left Interview

November 2, 2015 11:05 AM EST

Bouncing 8% in early trade after Citron Research dialed back on the explosiveness of its report, Valeant Pharma (NYSE: VRX) is on watch ahead of Citron's Andrew Left interview on CNBC at 12PM ET.

Left... More

Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday

November 1, 2015 7:32 PM EST

Citron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.

During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More